Research ArticleClinical Investigations
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sörensen, Dan Sandberg, Mattias Sandström, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Gunnar Åström, Mark Lubberink, Ulrike Garske-Román, Jörgen Carlsson and Henrik Lindman
Journal of Nuclear Medicine May 2014, 55 (5) 730-735; DOI: https://doi.org/10.2967/jnumed.113.131243
Jens Sörensen
1Nuclear Medicine and PET, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
Dan Sandberg
1Nuclear Medicine and PET, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
Mattias Sandström
1Nuclear Medicine and PET, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
Anders Wennborg
2Affibody AB, Solna, Sweden
Joachim Feldwisch
2Affibody AB, Solna, Sweden
3Biomedical Radiation Sciences, Rudbeck Laboratory, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden; and
Vladimir Tolmachev
3Biomedical Radiation Sciences, Rudbeck Laboratory, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden; and
Gunnar Åström
4Oncology, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
Mark Lubberink
1Nuclear Medicine and PET, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
Ulrike Garske-Román
1Nuclear Medicine and PET, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
Jörgen Carlsson
3Biomedical Radiation Sciences, Rudbeck Laboratory, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden; and
Henrik Lindman
4Oncology, Department of Radiology, Oncology, and Radiation Sciences, Uppsala University, Uppsala, Sweden
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 5
May 1, 2014
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sörensen, Dan Sandberg, Mattias Sandström, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Gunnar Åström, Mark Lubberink, Ulrike Garske-Román, Jörgen Carlsson, Henrik Lindman
Journal of Nuclear Medicine May 2014, 55 (5) 730-735; DOI: 10.2967/jnumed.113.131243
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
Jens Sörensen, Dan Sandberg, Mattias Sandström, Anders Wennborg, Joachim Feldwisch, Vladimir Tolmachev, Gunnar Åström, Mark Lubberink, Ulrike Garske-Román, Jörgen Carlsson, Henrik Lindman
Journal of Nuclear Medicine May 2014, 55 (5) 730-735; DOI: 10.2967/jnumed.113.131243
Jump to section
Related Articles
Cited By...
- Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer
- Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients
- Pretargeting: A Path Forward for Radioimmunotherapy
- Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection
- Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle
- First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
- Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology
- Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label
- In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds
- Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT
- Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside
- Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients
- Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
- Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
- ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers
- Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer
- 188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment